New drug combo targets recurrent ovarian cancer in small trial

NCT ID NCT07341100

Ongoing Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new drug called SKB264, given by IV every two weeks, in 20 women with recurrent ovarian epithelial cancer. It also looks at how the antibiotic clarithromycin affects SKB264 levels in the body. The main goals are to see if the drug shrinks tumors and to understand its safety and drug interactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB264 (a drug given by IV) and clarithromycin (an antibiotic taken by mouth)
What this could lead to: If it works, this could point toward a new treatment option for recurrent ovarian cancer.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer malignant epithelial tumor of ovary ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN EPITHELIAL CANCER

Contacts and locations

Show contact details

Locations

Sun Yat-sen University Cancer Center

Guangdong, Guangzhou, 510050, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.